Literature DB >> 24557566

Current thyroid cancer trends in the United States.

Louise Davies1, H Gilbert Welch2.   

Abstract

IMPORTANCE: We have previously reported on a doubling of thyroid cancer incidence-largely due to the detection of small papillary cancers. Because they are commonly found in people who have died of other causes, and because thyroid cancer mortality had been stable, we argued that the increased incidence represented overdiagnosis.
OBJECTIVE: To determine whether thyroid cancer incidence has stabilized.
DESIGN: Analysis of secular trends in patients diagnosed with thyroid cancer, 1975 to 2009, using the Surveillance, Epidemiology, and End Results (SEER) program and thyroid cancer mortality from the National Vital Statistics System.
SETTING: Nine SEER areas (SEER 9): Atlanta, Georgia; Connecticut; Detroit, Michigan; Hawaii; Iowa; New Mexico; San Francisco-Oakland, California; Seattle-Puget Sound, Washington; and Utah. PARTICIPANTS: Men and women older than 18 years diagnosed as having a thyroid cancer between 1975 and 2009 who lived in the SEER 9 areas.
INTERVENTIONS: None. MAIN OUTCOMES AND MEASURES: Thyroid cancer incidence, histologic type, tumor size, and patient mortality. RESULTS Since 1975, the incidence of thyroid cancer has now nearly tripled, from 4.9 to 14.3 per 100,000 individuals (absolute increase, 9.4 per 100,000; relative rate [RR], 2.9; 95% CI, 2.7-3.1). Virtually the entire increase was attributable to papillary thyroid cancer: from 3.4 to 12.5 per 100,000 (absolute increase, 9.1 per 100,000; RR, 3.7; 95% CI, 3.4-4.0). The absolute increase in thyroid cancer in women (from 6.5 to 21.4 = 14.9 per 100,000 women) was almost 4 times greater than that of men (from 3.1 to 6.9 = 3.8 per 100,000 men). The mortality rate from thyroid cancer was stable between 1975 and 2009 (approximately 0.5 deaths per 100,000). CONCLUSIONS AND RELEVANCE: There is an ongoing epidemic of thyroid cancer in the United States. The epidemiology of the increased incidence, however, suggests that it is not an epidemic of disease but rather an epidemic of diagnosis. The problem is particularly acute for women, who have lower autopsy prevalence of thyroid cancer than men but higher cancer detection rates by a 3:1 ratio.

Entities:  

Mesh:

Year:  2014        PMID: 24557566     DOI: 10.1001/jamaoto.2014.1

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  471 in total

1.  Macrometastasis in Papillary Thyroid Cancer Patients is Associated with Higher Recurrence in Lateral Neck Nodes.

Authors:  Soo Young Kim; Bup-Woo Kim; Ju Yeon Pyo; Soon Won Hong; Hang-Seok Chang; Cheong Soo Park
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

2.  Cancer-related worry in Canadian thyroid cancer survivors.

Authors:  Lauren Bresner; Rita Banach; Gary Rodin; Lehana Thabane; Shereen Ezzat; Anna M Sawka
Journal:  J Clin Endocrinol Metab       Date:  2014-11-13       Impact factor: 5.958

Review 3.  Transoral robotic thyroid surgery.

Authors:  James H Clark; Hoon Yub Kim; Jeremy D Richmon
Journal:  Gland Surg       Date:  2015-10

4.  The 8q24 rs6983267G variant is associated with increased thyroid cancer risk.

Authors:  Ruta Sahasrabudhe; Ana Estrada; Paul Lott; Lynn Martin; Guadalupe Polanco Echeverry; Alejandro Velez; Gila Neta; Meiko Takahasi; Vladimir Saenko; Norisato Mitsutake; Emma Jaeguer; Carlos Simon Duque; Alejandro Rios; Mabel Bohorquez; Rodrigo Prieto; Angel Criollo; Magdalena Echeverry; Ian Tomlinson; Luis G Carvajal Carmona
Journal:  Endocr Relat Cancer       Date:  2015-08-19       Impact factor: 5.678

5.  Germline PARP4 mutations in patients with primary thyroid and breast cancers.

Authors:  Yuji Ikeda; Kazuma Kiyotani; Poh Yin Yew; Taigo Kato; Kenji Tamura; Kai Lee Yap; Sarah M Nielsen; Jessica L Mester; Charis Eng; Yusuke Nakamura; Raymon H Grogan
Journal:  Endocr Relat Cancer       Date:  2015-12-23       Impact factor: 5.678

6.  MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.

Authors:  Hong-Ming Song; Yi Luo; Deng-Feng Li; Chuan-Kui Wei; Kai-Yao Hua; Jia-Lu Song; Hui Xu; Niraj Maskey; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Expression of BANCR promotes papillary thyroid cancer by targeting thyroid stimulating hormone receptor.

Authors:  Haitao Zheng; Jie Xu; Shaolong Hao; Xincheng Liu; Jinrao Ning; Xicheng Song; Lixin Jiang; Zongying Liu
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

Review 8.  The Role and Importance of Molecular Tests in Approach to Thyroid Nodules.

Authors:  Levent Gürbüzler
Journal:  Turk Arch Otorhinolaryngol       Date:  2016-04-06

9.  Early outcomes in transoral vestibular thyroidectomy: Robotic versus endoscopic techniques.

Authors:  Christopher R Razavi; Mai G Al Khadem; Akeweh Fondong; James H Clark; Jeremy D Richmon; Ralph P Tufano; Jonathon O Russell
Journal:  Head Neck       Date:  2018-05-13       Impact factor: 3.147

10.  Use of Dietary Vitamin Supplements and Risk of Thyroid Cancer: A Population-Based Case-Control Study in Connecticut.

Authors:  Christopher Kim; Huang Huang; Nan Zhao; Catherine C Lerro; Min Dai; Yingtai Chen; Ni Li; Shuangge Ma; Robert Udelsman; Yawei Zhang
Journal:  Int J Vitam Nutr Res       Date:  2017-04-24       Impact factor: 1.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.